Effect of polymyxin B-immobilized fiber hemoperfusion on respiratory impairment, hepatocellular dysfunction, and leucopenia in a neonatal sepsis model

Pediatr Surg Int. 2010 Feb;26(2):187-93. doi: 10.1007/s00383-009-2476-x. Epub 2009 Oct 3.

Abstract

Purpose: Sepsis and septic shock remain a major source of morbidity and mortality in neonates despite advances in antimicrobials and aggressive supportive care. Our aim was to study the effects of polymyxin-B direct hemoperfusion (PMX-DHP) therapy on sepsis-induced respiratory impairment, liver dysfunction and leucopenia in a neonatal cecal ligation and perforation (CLP) model.

Methods: Fourteen anesthetized and mechanically ventilated 3-day-old piglets underwent CLP and an arteriovenous extracorporeal circuit from 3 h until 6 h post-CLP, with a PMX column in the PMX-DHP treated group (7 piglets). Changes in oxygen saturation, PCO(2), base excess, white blood cell (WBC) count, platelet count, hematocrit (Hct%), serum glutamate pyruvate transaminase (SGPT), and serum glutamic oxaloacetic transaminase were measured before CLP and at 1, 3 and 6 h after.

Results: At 6 h, the PMX-DHP group showed lower Hct%, and SGPT in comparison to the control group, but higher oxygen saturation and WBC count. No effects on the platelet count were found. The survival times of the PMX-DHP group were longer than in control.

Conclusion: PMX-DHP therapy limited the respiratory impairment, liver dysfunction and leucopenia in a neonatal septic model, which resulted in an improvement of survival time.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Animals, Newborn
  • Anti-Bacterial Agents / pharmacology
  • Coated Materials, Biocompatible*
  • Disease Models, Animal
  • Follow-Up Studies
  • Hemoperfusion / methods*
  • Hepatocytes / pathology
  • Leukopenia / metabolism
  • Leukopenia / therapy*
  • Liver Diseases / metabolism
  • Liver Diseases / pathology
  • Liver Diseases / therapy*
  • Oxygen Consumption
  • Polymyxin B / pharmacology*
  • Polystyrenes
  • Respiratory Insufficiency / metabolism
  • Respiratory Insufficiency / therapy*
  • Sepsis / metabolism
  • Sepsis / therapy*
  • Swine
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Coated Materials, Biocompatible
  • Polystyrenes
  • Polymyxin B